"10.1371_journal.pone.0006963","plos one","2009-09-09T00:00:00Z","Grégory Lacraz; Marie-Hélène Giroix; Nadim Kassis; Josiane Coulaud; Anne Galinier; Christophe Noll; Mélanie Cornut; Fabien Schmidlin; Jean-Louis Paul; Nathalie Janel; Jean-Claude Irminger; Micheline Kergoat; Bernard Portha; Marc Y Donath; Jan A Ehses; Françoise Homo-Delarche","Laboratory of Biology & Pathology of Endocrine Pancreas, Functional and Adaptive Biology Unit-CNRS EA 7059, University Paris-Diderot, Paris, France; CNRS UMR 5241, P. Sabatier University, Institut L. Bugnard, Toulouse, France; Laboratory of Gene Dysregulation & Differentiation, Functional and Adaptive Biology Unit-CNRS EA 7059, University Paris-Diderot, Paris, France; Department of Genetic Medicine and Development, CMU, University of Geneva, Geneva, Switzerland; Merck Serono, Chilly-Mazarin, France; AP-HP, Hôpital Européen Georges Pompidou, Biochemistry Laboratory, Paris, France; Division of Endocrinology, Diabetes & Nutrition, University Hospital of Zürich, Zürich, Switzerland","Conceived and designed the experiments: GL NK JC AG CN MC FS JLP NJ MD JE FHD. Performed the experiments: GL MHG NK JC AG CN MC FS JLP NJ JE FHD. Analyzed the data: GL JCI MK MD JE FHD. Contributed reagents/materials/analysis tools: BP. Wrote the paper: GL JCI MD JE FHD.","M.Y.D is a consultant for Amgen, XOMA, Novartis, and Merck. M.Y.D is listed as the inventor on a patent (WO6709) filed in 2003 for the use of an interleukin-1 receptor antagonist for the treatment of or prophylaxis against type 2 diabetes. The patent is owned by the University of Zurich, and M.Y.D. has no financial interest in the patent. There are no other potential competing interests.","2009","09","Grégory Lacraz","GL",16,TRUE,12,12,6,5,TRUE,TRUE,FALSE,0,NA,FALSE
